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I. Starting with this issue, following an initiative from the 
Scientifi c Department of São Paulo Medical Association 
(Associação Paulista de Medicina, APM) and with support 
from the National Council for Scientifi c and Technological 
Development (Conselho Nacional de Desenvolvimento 
Científi co e Tecnológico, CNPq), for inclusion in the ISI 
database (Institute for Scientifi c Information), the São Paulo 
Medical Journal will be published with the subtitle “Evi-
dence for Health Care”. This change is being implemented 
because the culture of Evidence-Based Medicine is becoming 
increasingly consolidated in Brazil, thanks to initiatives from 
APM through the São Paulo Medical Journal, the journal 
Diagnóstico & Tratamento, the Scientifi c Department and 
the Board of Directors, and also through the television 
program “APM on the TV: Evidence-Based Medicine”, 
which is now back on the air, supported by the whole APM 
Board. Furthermore, we already have scientifi c production of 
quality and quantity to supply the initial editorial needs.
 The Journal will keep the same characteristics that have 
provided it with all the requisites for recognition of its 
international standards. It will be expanded to enable pub-
lication of articles that are deemed to provide evidence for 
clinical practice and implementation, such as systematic 
reviews following the Cochrane standards, summaries of 
Cochrane reviews, clinical management and evidence-based 
technological assessments.
 Authors of papers in these fi elds are more than welcome 
to submit their work for consideration. At the same time, 
following the practice of the Cochrane Collaboration to dis-
seminate the best evidence, articles of national interest may 
be reproduced in the São Paulo Medical Journal, provided 
that this is authorized by the Cochrane Library’s editors and 
the authors concerned, and this will be made clear in the 
Journal. In parallel with this, we will comply with all the 
requirements for the São Paulo Medical Journal to become 
indexed in the Web of Science (ISI).
II. In chapters on healthcare technology evaluations in two 
recently published books that are opportune and otherwise 
recommendable, the opinion given is that it is almost impos-
sible to accomplish such evaluations in Brazil, because of the 
lack of human resources and because of their complexity.1,2
 We completely disagree with this. This would signify total 
surrender in the face of a vital challenge for Brazilian Medi-
cine and would constitute a declaration of little faith in the 
quantity and quality of Brazilian healthcare professionals, 
including those with master’s and doctoral degrees who have 
already formally qualifi ed, and including those under the 
supervision of one of the authors cited. It also ignores all 
the good work developed by the Brazilian Cochrane Center, 
APM, the Brazilian Medical Association (Associação Médica 
Brasileira, AMB), the Ministry of Health, the National 
Agency for Sanitary Surveillance (Agência Nacional de 
Vigilância Sanitária, ANVISA) etc.
 Nonetheless, this controversy is good and we are not going 
to shy away from it. We take the view that everyone will 
have to agree that it only makes sense to proceed with a 
technological assessment on a new diagnostic, therapeutic or 
preventive method, if there is evidence regarding its effi cacy 
or effectiveness, at least. This is even clearer if there is no 
proof of its effi ciency and safety, considering that in these 
evaluations we are generally investigating the advantages of 
the new product in relation to non-intervention or other 
options. Therefore, if there is no reasonable evidence that, 
for example, the treatment has better performance than 
non-intervention in the real world, there is no justifi cation 
to continue to evaluate it technologically, with regard to 
its economic, management and safety characteristics, etc. 
Good-quality randomized clinical trials are a fundamental 
step in this process.
 For instance, if a type of prosthesis or medication is clearly 
less effective than and not as safe as a similar product, there 
is no economic evidence that can recommend it, no matter 
how fi nancially or managerially advantageous the item may 
be, since safety is essential. Moreover, without safety, there is 
little room to continue with a more pragmatic assessment. 
Nor does it make sense to continue with a technological as-
sessment on products when clinical trials on these products 
have demonstrated that their effect is no better than placebo, 
for example. 
 A study of ours that mapped out the evidence for fi rst-
level healthcare decisions (Cochrane systematic reviews)3 
showed that for 50% of the treatments reviewed, not even 
a comparative clinical trial had been published, and that 
in less than 10% of the interventions was there suffi cient 
certainty for further studies not to be justifi ed. In other 
words, in 50% or more of the occasions, an assessment of the 
evidence relating to effectiveness, effi ciency and safety would 
be enough to complete the process of technological assess-
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ment, which has the aim of achieving 
more immediate implementation. Hence, 
adequate mapping of the evidence is es-
sential for the technological assessment 
of any procedure, and this will resolve a 
large proportion of the cases. We reem-
phasize that mapping out the evidence is 
mandatory for starting the process, and 
it may often finish the process. When 
there is evidence that an item is effective 
and safe, then indeed we can move on to 
evaluations of the economics, efficiency, 
management, ethics and so on.
III. The impact factor of the Cochrane Library 
in the ISI database (see Annex) has been 
measured as 4.65. This is several times 
greater than the impact factor of the 
Brazilian medical journal that is most 
cited, the Brazilian Journal of Medical 
and Biological Research. Congratulations 
to the several hundred reviewers of the 
Brazilian Cochrane Collaboration and 
our thanks to everyone who collaborated 
in this historic undertaking.
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Dear all,
The 2007 impact factors (IFs) have now been published by Thomson ISI, and the Cochrane Database of Systematic Reviews has an IF of 4.654 and is ranked 
14 out of 100 in the ISI category Medicine, General & Internal.
Congratulations to you all.
The 2007 IF is calculated on the total number of cites in 2007 to articles published in 2006 (2442 cites) and in 2005 (2798 cites) total = 5,240 divided by the total 
number of articles published in 2006 (575) and 2005 (551) total= 1126.
As noted in my previous email, we will be analyzing the data available from ISI to form future communications. In the meantime, should you have any questions 
please feel free to contact me.
Best wishes,
Deborah Pentesco-Gilbert. 
Associate Editorial Director. 
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